Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

4.270 -0.040 (-0.93%)
Delayed Quote Updated: 12:34 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 685,093
Open 4.350
Bid (Size) 4.260 (300)
Ask (Size) 4.270 (300)
Prev. Close 4.310
Today's Range 4.165 - 4.395
52wk Range 4.000 - 13.15
Shares Outstanding 95,568,307
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kaplan Fox Reminds Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Securities Class Action Deadline - Contact the Firm Before October 5, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-62.8%
-62.8%
1 Month
-28.8%
-28.8%
3 Month
-46.2%
-46.2%
6 Month
-47.3%
-47.3%
1 Year
-57.5%
-57.5%

More News

Read More
News headline image
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Who Suffered Losses to a Securities Class Action – Deadline is October 5, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm Before Lead Plaintiff Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
Kaplan Fox Alerts Investors to an Upcoming Deadline of October 5, 2026 in the ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Securities Class Action
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
Kaplan Fox Reminds ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Seek a Leadership Role Before Deadline on October 5, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026
Via NewMediaWire
Topics Fraud Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors with Significant Losses to Contact the Firm Before October 5, 2026
From Kaplan Fox & Kilsheimer, LLP
Via GlobeNewswire
News headline image
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and Lead Plaintiff Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Lead Plaintiff Deadline is October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
The current price of ARS Pharmaceuticals, Inc. - Common Stock is 4.270
When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 10/01/26 12:34 PM ET
What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 408.08M
How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
ARS Pharmaceuticals, Inc. - Common Stock has 408M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.